Neoadjuvant Chemotherapy Combined with Immunotherapy

Phase 2Small molecule

OObstetrics & Gynecology Hospital of Fudan University

Neoadjuvant Chemotherapy Combined with Immunotherapy is one of 62 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Cervical CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Halaven

Eisai

Preclinical

38 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

MS Contin

Merck & Co.

Preclinical

2 6

Zolymbus

AbbVie

Preclinical

1 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Neoadjuvant Chemotherapy Combined with Immunotherapy

OObstetrics & Gynecology Hospital of Fudan University

Phase 2

1 9

Acupan

YYonsei University

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Breast Cancer

NCT06908668

Q3 2030

Phase 2Recruiting

Cervical Cancer

NCT07130240

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer

Recruiting·OObstetrics & Gynecology Hospital of Fudan University·Phase 2·NCT07130240·20 enrolled

Breast Cancer1 trial

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Not yet recruiting·—·Phase 2·NCT06908668·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Neoadjuvant Chemotherapy Combined with Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant Chemotherapy Combined with Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant Chemotherapy Combined with Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Obstetrics & Gynecology Hospital of Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OObstetrics & Gynecology Hospital of Fudan University

Neoadjuvant Chemotherapy Combined with Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2030

Trials by Indication[1]

Cervical Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News